Contract Manufacturing Services

Spray Drying Finds Growing Use for ASDs

February 01, 2022

CDMOs offer expertise and capacity for spray drying.

Samsung Biologics to Acquire Full Ownership of Samsung Bioepis in $2.3 Billion Deal

January 28, 2022

Samsung Biologics has signed an agreement with Biogen to acquire Biogen’s 50% stake in Samsung Bioepis, a joint venture formed by the two companies, for up to $2.3 billion.

Cyxone Engages European CDMO for Scale-Up and Production of T20K

January 21, 2022

Cyxone has appointed a European CDMO to scale-up and produce the active ingredient of its T20K drug candidate.

Drug Solutions Podcast: 2022 Bio/pharma Trends: US-Based Suppliers, Digitization, and Sustainability

January 18, 2022

In this episode of the Drug Solutions podcast, Chris Spivey, editorial director, and Meg Rivers, senior editor, interview experts on up-and-coming 2022 trends in the bio/pharma industry.

Merck KGaA Acquires CDMO Exelead

January 11, 2022

The agreeement will add to Merck KGaA’s LNP and mRNA capabilities.

Piramal Pharma Invests Minority Stake in India-Based CDMO, Yapan Bio

January 05, 2022

With this investment into Yapan Bio, Piramal Pharma adds new technologies and capabilities in large molecules, including vaccines and gene therapies, to its global offering.

The Need for Speed: How Operation Warp Speed Shifted the Pharma Industry

January 03, 2022

A new focus on speed to market creates challenges for facility design and construction.

FUJIFILM Irvine Scientific Opens New European Manufacturing Facility

December 16, 2021

FUJIFILM Irvine Scientific’s new manufacturing facility in Tilburg, the Netherlands, is now fully operational.

FUJIFILM Diosynth Biotechnologies to Create Major Biopharma Manufacturing Site in United Kingdom

December 16, 2021

FUJIFILM Diosynth Biotechnologies plans to invest £400 million (US$528 million) to expand its Billingham, Teeside facility in the United Kingdom.

Lonza and Bioqube Ventures Form Agreement for Future Development and Manufacture of Biologics and Small Molecules

December 09, 2021

Lonza has signed a five-year services agreement to provide for the development and manufacturing of biologics and small molecules for portfolio companies owned by Bioqube Ventures.